Metoprolol in Patients With HFrEF and COPD

Metoprolol in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease

NCT06825728•Xiangya Hospital of Central South University

Summary

The goal of the clinical trial was to see if Metoprolol was effective in treating patients with heart failure and chronic obstructive pulmonary disease. It will also learn about the safety of Metoprolol. The main questions it aims to answer are: Did Metoprolol reduce the frequency of all-cause deaths and re-hospitalizations in subjects? What medical problems do participants experience after taking Metoprolol? The researchers will compare different doses of Metoprolol to see the best dose for Metoprolol. Participants will: Take Metoprolol 23.75mg/ day or the maximum tolerable dose of Metoprolol daily for 24 months. Regular outpatient follow-up visits to the research center. Their symptoms and Metoprolol dosage were recorded.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. A definite diagnosis of HFrEF (LVEF≤40%), NYHA II to IV , and the disease is due to ischemic heart disease or dilated cardiomyopathy;
•2. A definite diagnosis of COPD with moderate or higher airflow limitation (FEV1/FVC \< 0.7 and FEV1 \< 80% of the expected value);
•3. Age ≥18 years old;
•4. Informed consent has been obtained and signed.

Exclusion Criteria

•1. the dose of Metoprolol before enrollment was more than 23.75mg/d;
•2. Resting heart rate \< 50 beats/min;
•3. Second or third degree atrioventricular block;
•4. Atrial fibrillation;
•5. Sick sinus syndrome;
•6. Systolic blood pressure \< 90mmHg;
•7. Acute attack of bronchial asthma;
•8. Liver insufficiency (serum transaminase \> 3 times the normal value);
•9. Renal insufficiency (eGFR \< 30ml/min/1.73m2, or serum creatinine \> 2.5mg/dL\[\> 221μmol/L\]);
•10. Patients with serious physical diseases, such as cancer;
+5 more criteria

Key Dates

Start Date

February 1, 2025

Primary Completion Date

February 1, 2028

Completion Date

February 1, 2028

Last Updated

February 13, 2025

Enrollment

311

ESTIMATED participants

Conditions

Heart Failure With Reduced Ejection Fraction (HFrEF)COPD (Chronic Obstructive Pulmonary Disease)

Interventions

Different doses of Metoprolol.

DRUG

Probiotics in Pulmonaty Rehabilitation for COPD

NCT06717659

COPD (Chronic Obstructive Pulmonary Disease)Probiotic Intervention+1 more

View study

RECRUITINGNA

Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation

NCT07072039

COPD (Chronic Obstructive Pulmonary Disease)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Metoprolol in Patients With HFrEF and COPD

Inclusion Criteria

Exclusion Criteria

Probiotics in Pulmonaty Rehabilitation for COPD

Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Effectiveness of DITM Versus IMT in COPD Patients

Clinical Pilates Programme on People With COPD Gold A: a Rehabilitation Nursing Approach.

Investigation of the Effects of Different Exercise Approaches on Clinical Parameters in Chronic Obstructive Pulmonary Disease Patients